Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) increased by nearly 5%, reaching HKD 13.62, with a trading volume of HKD 15.42 million following the announcement of a collaboration agreement with AstraZeneca [1] Group 1: Company Developments - On November 24, HAPO Pharmaceutical-B announced that its indirect wholly-owned subsidiary, HAPO Pharmaceutical (Shanghai) Co., Ltd. (HAPO Shanghai), entered into a collaboration, option, and licensing agreement with AstraZeneca PLC [1] - The collaboration aims to expand the scope of their partnership, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers [1] - The economic terms and financial framework established under the collaboration agreement remain consistent with previous agreements [1]

Core Viewpoint - The collaboration between 和铂医药-B and AstraZeneca aims to leverage both companies' expertise to discover and develop next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers, under a revised agreement set to take effect on November 24, 2025 [1] Group 1 - 和铂医药-B's indirect wholly-owned subsidiary, 和铂医药(上海)有限责任公司, has entered into a collaboration, option, and licensing agreement with AstraZeneca PLC [1] - The scope of collaboration has been further expanded following the revision of the agreement between 和铂上海 and AstraZeneca [1] - The economic terms and financial framework established under the collaboration agreement remain consistent [1]